Parabilis Medicines
Cambridge, Massachusetts, United States · Biopharma, Biotechnology, Health Care
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blo
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 170
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (PBLS)
- Website
- parabilis.com
- Company page
Recent activity at Parabilis Medicines
- : Parabilis Medicines Appoints Craig Tendler as Director
- : Parabilis Medicines secures $305 million in Series F funding led by RA Capital Management to advance FOG-001 clinical development and support its innovative Helicon platform.
- : Parabilis Medicines Appoints Fawzi Benzaghou as Chief Medical Officer
- : Parabilis Medicines Announces Corporate Name Change and Unveils Helicon Platform for Drug Discovery
Parabilis Medicines funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2026 | Series F | $305.0M |
Leadership
- Mathai Mammen, Chairman, CEO and President
- Craig Tendler, Director
- Gregory Miller, Chief Business Officer
- Fawzi Benzaghou, Chief Medical Officer
Verified email and direct lines for Parabilis Medicines’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Parabilis Medicines files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Parabilis Medicines in the news
- Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Yahoo Finance (Sep 01, 2026)
- Parabilis Medicines to Present Updated Clinical Data for - GlobeNewswire (Oct 19, 2026)
- Parabilis Medicines Raises $670 Million in Initial Public Offering - Pharmaceutical Executive (Jun 10, 2026)
- Cancer-focused Parabilis’ upsized $670M IPO breaks new record for biotechs - Fierce Biotech (Jun 10, 2026)
- After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets - BioPharma Dive (May 20, 2026)
- Parabilis Medicines raises record $670 million in biotech IPO - Quartz (Jun 11, 2026)
- Parabilis Medicines Shares Rocket Following Record Biotech IPO - WSJ (Jun 10, 2026)
- Regeneron Expands Conjugate Platform Strategy Through Parabilis Medicines Collaboration - BioPharm International (May 18, 2026)
Companies similar to Parabilis Medicines
- Disc · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- TerSera · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Supernus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Aurinia Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Avadel · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Parabilis Medicines: questions and answers
What does Parabilis Medicines do?
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blo
Where is Parabilis Medicines headquartered?
Parabilis Medicines is headquartered in Cambridge, Massachusetts, United States.
How many employees does Parabilis Medicines have?
Parabilis Medicines has about 170 employees.
Has Parabilis Medicines raised funding?
Yes. Fundz has recorded 1 funding event for Parabilis Medicines. The most recent, Series F of $305.0M, was in Jan 2026.
Who leads Parabilis Medicines?
Mathai Mammen is a Chairman, CEO and President at Parabilis Medicines.
What is the latest news on Parabilis Medicines?
On Aug 25, 2026, Parabilis Medicines Appoints Craig Tendler as Director
Is Parabilis Medicines a public company?
Yes. Parabilis Medicines is publicly traded under the ticker PBLS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy